the Geriatric Depression Scale (GDS), first created by Yesavage et al., has been tested and used extensively with the older population. It is a brief questionnaire in which participants are asked ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

−5.53 (IQR=−6.24 to –4.81), The Edinburgh Postnatal Depression Scale: −2.97 (IQR=−3.49 to –2.44), self-rating scale: −3.99 (one review), Brief Symptom Inventory 18: −3.02 (one review), Centre for ...

Early Alzheimer's pathology was not consistently linked to depressive symptoms in people without clinical dementia, cross-sectional data suggested. In people with normal cognition, depressive symptoms ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

On day 28 of the trial, patients taking Spravato exhibited numerical improvements for all 10 items on the Montgomery-Asberg ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The Center for Epidemiological Studies-Depression Scale was used to measure the risk of depression at the beginning of the study (12–16 weeks), at gestational week 38 and at 6 weeks postpartum.

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet ...